BostonGene and Unilever are starting a strategic collaboration in scientific exploration and long-term innovation. As developer of an artificial intelligence (AI) foundation model for tumor and immune biology, BostonGene will leverage proprietary analytical capabilities. Unilever, meanwhile, is a leader in consumer goods, with its products used daily by 3.7 billion people in 190 countries. To that scientific expertise, BostonGene plans to add omnimodal data integration and advanced AI capacit...